SGCG gene

Limb-girdle muscular dystrophy type 2C (LGMD2C), caused by SGCG mutations, often presents in childhood or early adulthood with progressive weakness in the hips, shoulders, and upper arms. Early signs may include difficulty climbing stairs, frequent tripping, or a waddling gait. Over time, the weakness spreads to the legs and arms, potentially affecting the ability to stand from a seated position or lift objects overhead. While the disease is progressive, the rate of decline varies significantly among individuals, and some patients may retain ambulation for decades. What specific genetic tests are used to confirm an SGCG-related diagnosis, and can a carrier status be determined?::Diagnosis is typically confirmed through genetic testing that sequences the SGCG gene to identify pathogenic variants. This is often part of a broader panel for limb-girdle muscular dystrophy. Carrier testing is available for family members and involves analyzing the specific variant found in the affected individual. Since LGMD2C is autosomal recessive, carriers (heterozygotes) usually do not show symptoms but have a 25% chance of passing two affected copies to their children if both parents are carriers. Are there any specific lifestyle modifications or therapies that can help manage symptoms associated with SGCG mutations?::Management focuses on maintaining mobility and preventing complications. Physical therapy is crucial to maintain range of motion and prevent contractures, while orthopedic interventions may be needed for scoliosis or hip issues. Cardiac monitoring is recommended because some patients may develop heart muscle involvement, although this is less common than in other dystrophies. There is currently no cure, but supportive care, including respiratory monitoring if weakness progresses, helps improve quality of life.